Immunotherapy toxicities: An SGO clinical practice statement.
作者信息
O'Cearbhaill R E, Clark L, Eskander R N, Gaillard S, Moroney J, Pereira E, Pothuri B
机构信息
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
University of North Carolina, Chapel Hill, NC, USA.
出版信息
Gynecol Oncol. 2022 Jul;166(1):25-35. doi: 10.1016/j.ygyno.2022.05.003. Epub 2022 May 18.
Abstract
摘要
相似文献
1
Immunotherapy toxicities: An SGO clinical practice statement.
Gynecol Oncol. 2022 Jul;166(1):25-35. doi: 10.1016/j.ygyno.2022.05.003. Epub 2022 May 18.
2
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
3
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Support Care Cancer. 2020 Dec;28(12):6129-6143. doi: 10.1007/s00520-020-05707-3. Epub 2020 Aug 27.
4
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.
5
Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy.
Eur J Cancer. 2021 Sep;155:38-41. doi: 10.1016/j.ejca.2021.06.036. Epub 2021 Aug 2.
6
Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
Curr Treat Options Oncol. 2019 Nov 21;20(11):83. doi: 10.1007/s11864-019-0679-5.
7
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
J Cutan Pathol. 2018 Jul;45(7):504-507. doi: 10.1111/cup.13150. Epub 2018 Apr 23.
8
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Curr Treat Options Oncol. 2018 Nov 5;19(12):70. doi: 10.1007/s11864-018-0593-2.
9
Immune Checkpoint Inhibitor Toxicities.
Mayo Clin Proc. 2019 Jul;94(7):1321-1329. doi: 10.1016/j.mayocp.2019.03.012.
10
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Expert Rev Clin Pharmacol. 2016;9(3):419-28. doi: 10.1586/17512433.2016.1133289. Epub 2016 Feb 6.
引用本文的文献
1
Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer.
Gynecol Oncol Rep. 2025 Jun 22;60:101791. doi: 10.1016/j.gore.2025.101791. eCollection 2025 Aug.
2
Immune checkpoint Inhibitor-Induced Autoimmune hemolytic anemia in endometrial cancer.
Gynecol Oncol Rep. 2025 Apr 17;59:101746. doi: 10.1016/j.gore.2025.101746. eCollection 2025 Jun.
3
The Impact of Immunotherapy on Sleep and Circadian Rhythms in Patients with Cancer.
Front Oncol. 2023 Nov 27;13:1295267. doi: 10.3389/fonc.2023.1295267. eCollection 2023.
本文引用的文献
1
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020.
2
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.
3
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
4
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
JAMA Oncol. 2020 Nov 1;6(11):1766-1772. doi: 10.1001/jamaoncol.2020.4515.
5
A review of cancer immunotherapy toxicity.
CA Cancer J Clin. 2020 Mar;70(2):86-104. doi: 10.3322/caac.21596. Epub 2020 Jan 16.
6
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.
7
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
8
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.
9
Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin.
J Clin Neurol. 2019 Apr;15(2):259-261. doi: 10.3988/jcn.2019.15.2.259. Epub 2019 Mar 11.
10
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Gynecol Oncol. 2019 Feb;152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. Epub 2018 Dec 3.
Zotero 插件